| Gene |
NHL Patients (number-%) |
Controls (number-%) |
OR |
95% CI |
P value |
| CASP8 D302H
•
Wild genotype CC
• HeterotypeCG
• Homotype GG
• CG and GG |
9(9%)
7(7%)
84(84%)
91(91%) |
49(49%)
6(6%)
45(45%)
(51%) |
Reference
1.179
6.417
9.715 |
0.382-3.641
3.303-12.466
4.413-21.387 |
0.774
<0.001
<0.001 |
| CAS8 6N 652 ins/del
•
Wild genotype ins/ins
• Heterotype ins/del
• Homotype del/del
• Ins/del and del/del |
19(19%)
44(44%)
37(37%)
81(81%) |
20(20%)
46(46%)
34(34%)
80(80%) |
Reference
0.966
1.140
0.886 |
0.55-1.677
0.639-2.035
0.508-1.546 |
0.887
0.658
0.671 |
| CASP 10 I522L
• Wild genotype TT
•
HeterotypeTA
•
Homotype AA
•
TA and AA
|
48(48%)
43(43%)
9(9%)
52(52%) |
45(45%)
41(41%)
14(14%)
55(55%) |
Reference
1.08
0.608
0.938 |
0.619-1.904
0.250-1.476
0.466-1.889 |
0.774
0.268
0.858 |
| Dual CASP8 D302H / CASP8-652 6N ins/del mutation |
74(74%) |
40(40%) |
4.269 |
2.344-7.777 |
<0.0001 |
| Dual CASP 8 D302H / CASP10 I522L mutation |
47(47%) |
31(31%) |
1.974 |
1.108-3.517 |
0.020 |
| Dual CASP 8-652 6N ins/del /CASP 10 I522L mutation |
39(39%) |
40(40%) |
0.959 |
0.959-0.554 |
0.885 |
| Triple mutation |
35(35%) |
24 (24%) |
1.705 |
0.921-3.157 |
0.088 |